Pamela Carroll

Founded in 1898, Northeastern University is a private research university located in the heart of Boston. Northeastern teaches worldwide experiential learning, urban engagement, and interdisciplinary research that meets global and societal needs. The University offers a range of undergraduate and graduate programs leading to degrees through the doctorate in nine colleges and schools.

Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA.

Launchpad Therapeutics, Inc. develops novel therapeutics.

858 Therapeutics, Inc. operates as a pharmaceutical company. The company was founded in 2019 and is headquartered in San Diego, CA.

Sanofi-Aventis U.S. LLC engages in the provision of pharmaceutical products. It discovers, develops, produces and markets innovative therapies. The firm extensive research and development efforts are focused on health care challenges in cardiology, oncology and internal medicine, as well as metabolic diseases, central nervous system disorders, ophthalmology and vaccines. The company is headquartered in Bridgewater, NJ.

Tune Therapeutics, Inc. is a genetic medicine company based in Durham, NC. Tune Therapeutics is pioneering a new therapeutic modality with its versatile and powerful tempo epigenomic control platform. The platform has the potential to fine-tune any gene network and unlock the full power and potential of regenerative medicine. The company is driving through an inflection point in the history of genetic medicine by addressing thousands of common and complex diseases for which no curative treatment is available. Tune Therapeutics pioneers next-generation genetic therapies by exploring epigenomic control for discovering novel targets that are inaccessible to other approaches. The company was founded in 2020 by Fyodor Urnov, Akira Matsuno, Charles A. Gersbach. The CEO is Matt Kane.

AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden.

Pharmaceutical Research & Manufacturers of America provides pharmaceutical research and biotechnology services. It represents the country’s biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. The company was founded in 1958 and is headquartered Washington, DC.

Acerta Pharma BV develops drugs for oncology and autoimmune diseases. It operates as a biotech company that combines technology platforms in drug discovery and development such as the covalent technology platform and the multiparametric phosphoflow cytometry platform. The company was founded by Allard Kaptein in 2012 and is headquartered in Oss, Netherlands.

AstraZeneca Pharmaceuticals LP develops, manufactures and markets prescription pharmaceutical drugs. It sells products related to gastrointestinal, cardiovascular, neuroscience, respiratory and oncology infections. The company was founded in 1953 and is headquartered in Wilmington, DE.

Part of AstraZeneca PLC, AstraZeneca Holding GmbH functions as an investment holding German company. The company is based in Wedel, Germany. The CEO of the company is Hans Sijbesma.

AstraZeneca UK Ltd. manufactures pharmaceutical products. Its products are used to treat cardiovascular diseases, diabetes, and gastrointestinal infections. The company was founded on November 26, 1998 and is headquartered in London, the United Kingdom.

Korro Bio, Inc. engages in the development of a bio therapeutics. It focuses on a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in protein structure and function across multiple tissues. The company was founded by Jean-Fran?ois Formela, Josh Rosenthal, Nessan Bermingham, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA.

Stablix, Inc. is a biotechnology company based in New York, NY. The company is focused on establishing a new paradigm for tackling diverse diseases by harnessing the power of the body's own cellular machinery through targeted protein stabilization. Stablix's restored™ platform generates heterobifunctional small molecules (restoracs™) that selectively recruit active deubiquitinases (dubs) to target proteins for precise removal of ubiquitin to restore protein function. The company is currently advancing its lead programs towards clinical studies. The company's platform is based on the work of Henry Colecraft, Ph.D., professor of physiology and cellular biophysics, and professor of pharmacology, Columbia University Irving Medical Center. Stablix was founded in June 2021 with a $63 million series A led by founding investor Versant Ventures with New Enterprise Associates (NEA), Cormorant Asset Management, Euclidean Capital, and Alexandria Venture Investments. Stuart Anthony Kingsley has been the CEO of the company since 2022.

New Enterprise Associates LLC (New Enterprise Associates) is a venture capital firm founded in 1977. The firm headquartered in Menlo Park, California.

Duke University is an academic university that offers undergraduate, graduate and professional programs. It also has publications and research services. The university was founded in 1838 and is headquartered in Durham, NC.

Ocutherix, Inc. operates as a medical device incubator which focuses on novel medical technologies. The firm serves the ophthalmology, cardiology, mobile health, orthopedics, neurology, pulmonology and metabolic clinical solutions. The company was founded by Robert E. Atkinson in 2005 and is headquartered in Stillwater, MN.

Rotation Medical, Inc. develops treatment of rotator cuff disease. It includes a bioinductive implant and a set of disposable arthroscopic instruments that has been shown to heal tendons by inducing the growth of new tendon-like tissue. The company was founded by Thomas R. Hektner in 2009 and is headquartered in Plymouth, MN.

Solace Therapeutics, Inc. develops non-surgical treatments for common bladder disorders. It offers medical devices for stress urinary incontinence, overactive bladder, male voiding dysfunction, and lower urinary tract symptoms. The company was founded by Kevin G. Connors in 2002 and is headquartered in Framingham, MA.

Adaptimmune Ltd. develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroy cancerous and infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was founded by Bent K. Jakobsen, James Julian Noble and Helena Katrina Tayton-Martin in 2008 and is headquartered in Oxford, the United Kingdom.

Ivantis, Inc. develops technology to treat ophthalmic diseases. The firm develops solutions for glaucoma and offers an intracanalicular scaffold or implantable device that relieves high intraocular pressures in patients. It provides its solutions for use in clinical trials to ophthalmology specialists. Ivantis was founded in 2007 and is headquartered in Irvine, CA.

ClarVista Medical, Inc. operates as a medical device company which focuses on the novel solutions in ophthalmology. It develops the harmoni modular intra-ocular lens systems to optimize vision in the setting of cataract surgery. The company was founded by Paul McLean and Robert E. Atkinson in 2012 and is headquartered in Aliso Viejo, CA.